Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.

Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.

Item
http://www.wikidata.org/entity/Q33856836
Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme ActivityPrediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic ModelEffect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease.Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension.
P2860

Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.

Item
http://www.wikidata.org/entity/Q33856836
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Simulation of clinical drug-dr ...... tial utility in trial designs.
@ast
Simulation of clinical drug-dr ...... tial utility in trial designs.
@en
type
label
Simulation of clinical drug-dr ...... tial utility in trial designs.
@ast
Simulation of clinical drug-dr ...... tial utility in trial designs.
@en
prefLabel
Simulation of clinical drug-dr ...... tial utility in trial designs.
@ast
Simulation of clinical drug-dr ...... tial utility in trial designs.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Simulation of clinical drug-dr ...... tial utility in trial designs.
@en
P2093
P304
P31
P356
P433
P478
P577
P698